Plerixafor use in New Zealand 2016-2019: an observational study.

Published in: Internal medicine journal (2022)

Plerixafor strategies in New Zealand allow successful stem cell mobilisation for ≥96% of patients. Further research is required to investigate whether increased use would be cost-effective through reduced chemotherapy and apheresis duration, and improved graft quality.

Keyphrases

stem cells
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
radiation therapy
locally advanced
cell therapy
rectal cancer